KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Change in Accured Expenses (2016 - 2026)

Pacira BioSciences has reported Change in Accured Expenses over the past 17 years, most recently at $3.3 million for Q1 2026.

  • For Q1 2026, Change in Accured Expenses fell 30.07% year-over-year to $3.3 million; the TTM value through Mar 2026 reached $5.4 million, down 72.68%, while the annual FY2025 figure was $6.9 million, 52.52% down from the prior year.
  • Change in Accured Expenses for Q1 2026 was $3.3 million at Pacira BioSciences, up from $1.8 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $15.6 million in Q4 2024 and troughed at -$24.0 million in Q3 2022.
  • A 5-year average of -$993352.9 and a median of $421000.0 in 2023 define the central range for Change in Accured Expenses.
  • On a YoY basis, Change in Accured Expenses climbed as much as 8630.97% in 2022 and fell as far as 2273.51% in 2022.
  • Year by year, Change in Accured Expenses stood at $3.7 million in 2022, then crashed by 684.53% to -$21.6 million in 2023, then skyrocketed by 172.21% to $15.6 million in 2024, then tumbled by 88.65% to $1.8 million in 2025, then soared by 85.34% to $3.3 million in 2026.
  • Business Quant data shows Change in Accured Expenses for PCRX at $3.3 million in Q1 2026, $1.8 million in Q4 2025, and -$5.8 million in Q3 2025.